Kura Oncology reports 35% CR rate with ziftomenib in NPM1-mutant AML at EHA 2023

Kura Oncology, Inc.

7 of 20 NPM1-mutant AML patients at 600 mg RP2D achieved complete remission (CR) with full count recovery.
Median duration of response 8.2 months; median follow-up 8.8 months; 2 patients underwent SCT and remain in remission.
MEN1-M3271 resistance mutation detected in only 1 of 29 patients post-ziftomenib; ziftomenib active against MEN1-T349M.
Phase 2 registration-directed study (85 patients, 62 sites) enrollment outperforming projections; combination studies initiating.
Differentiation syndrome manageable: 15% Grade 1/2, 5% Grade 3; safety profile consistent with underlying disease.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.